Semaglutide trial finds slower biological aging markers (opens in new tab)

A randomized, double-blind, placebo-controlled clinical trial found that semaglutide, a GLP-1 drug used for weight loss and diabetes, was associated with slower biological aging markers in adults living with HIV. The study, published in Nature Communications, involved 108 adults with HIV-associated lipohypertrophy who received weekly semaglutide or placebo injections for 32 weeks. Researchers used epigenetic clocks to assess biological age. The clocks estimate aging-related changes by analyzi...